More Company News

HUTCHMED

Submission of fruquintinib Japan NDA in mCRC
29 Sep 2023Read More

HUTCHMED

Presentation of results from the Phase IIIb trial of savolitinib at WCLC 2023
12 Sep 2023Read More

HUTCHMED

Completion of enrollment in tazemetostat China bridging study in r/r FL
12 Sep 2023Read More

HUTCHMED

BTD granted in China for savolitinib in Gastric Cancer
29 Aug 2023Read More

HUTCHMED

Sovleplenib ITP Phase III met primary endpoint in China
21 Aug 2023Read More

HUTCHMED

H123 interim results & business update
31 Jul 2023Read More

HUTCHMED

China BTD for fruquintinib combo in advanced endometrial cancer
20 Jul 2023Read More

HUTCHMED

Start of HMPL-415 Phase I study in China
10 Jul 2023Read More

HUTCHMED

Phase III FRESCO-2 results published in The Lancet
16 Jun 2023Read More

HUTCHMED

Fruquintinib MAA accepted by EMA for mCRC
15 Jun 2023Read More

1 2 3 4 … 16
Return to HUTCHMED
© 2019-22 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).